Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skin Diseases AND Psoriasis Vulgaris AND Plaque Psoriasis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    75 result(s) found for: Skin Diseases AND Psoriasis Vulgaris AND Plaque Psoriasis. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2015-000943-17 Sponsor Protocol Number: NL54557.091.15 Start Date*: 2016-02-11
    Sponsor Name:Radboudumc
    Full Title: Tight control dose reductions of biologics in psoriasis patients with low disease activity: a randomized pragmatic trial.
    Medical condition: Adult Patients diagnosed psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10015581 Exacerbation of psoriasis LLT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037155 Psoriasis and similar disorders LLT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037156 Psoriasis flare-up LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-006057-28 Sponsor Protocol Number: CAIN457A2308 Start Date*: 2012-06-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate efficacy after twelve weeks of treatment, and to assess the safety...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000253-30 Sponsor Protocol Number: LP0075-34 Start Date*: 2012-11-08
    Sponsor Name:LEO Pharma A/S
    Full Title: An exploratory study evaluating the efficacy of cromoglicate cream compared to cream vehicle in the treatment of itch in psoriasis
    Medical condition: itchy psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001568-12 Sponsor Protocol Number: 16-02/CalciBet-S Start Date*: 2016-10-18
    Sponsor Name:Dermapharm AG
    Full Title: A multi-centre, randomised, double-blind, parallel-group phase III study to investigate the efficacy, safety, and tolerability of a generic calcipotriol-betamethasone ointment formulation compared ...
    Medical condition: chronic stable plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    19.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    19.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-023512-13 Sponsor Protocol Number: CAIN457A2302 Start Date*: 2011-05-24
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled, multi-center study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability and lo...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) IS (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017234-51 Sponsor Protocol Number: CAIN457A2211E1 Start Date*: 2010-04-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter extension trial of subcutaneously administered AIN457 in patients with moderate to severe chronic plaque-type psoriasis
    Medical condition: Moderate to severe plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IS (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2015-005170-38 Sponsor Protocol Number: CAIN457A2323 Start Date*: 2016-09-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, 52-weeks study to demonstrate the efficacy, safety and tolerability of subcutaneous secukinumAb injections with 2 mL pre-fiLLed syringes...
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) LV (Completed) BE (Completed) ES (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2013-003434-32 Sponsor Protocol Number: CAIN457A2317 Start Date*: 2014-01-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to uste...
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) AT (Completed) GB (Completed) DE (Completed) PT (Completed) IT (Completed) SK (Completed) BE (Completed) HU (Completed) GR (Completed) EE (Completed) BG (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-022228-66 Sponsor Protocol Number: CAIN457A2303 Start Date*: 2011-08-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, double-dummy, placebo controlled, multicenter study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, compared to placebo and etanerce...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FI (Completed) IS (Completed) HU (Completed) SE (Completed) BE (Completed) PL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002423-26 Sponsor Protocol Number: CAIN457A2322 Start Date*: 2016-12-16
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A randomized, multicenter Study to evaluate the Effect of secukinumab 300 mg s.c. administered during 52 Weeks to patients suffering from new-onset moderate to severe plaque Psoriasis as early Inte...
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FI (Completed) GB (GB - no longer in EU/EEA) EE (Prematurely Ended) SE (Prematurely Ended) NO (Completed) DK (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000767-27 Sponsor Protocol Number: CAIN457A2304 Start Date*: 2011-07-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to sever...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) DE (Completed) CZ (Completed) SK (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004467-20 Sponsor Protocol Number: AVXCLIN002 Start Date*: 2014-12-10
    Sponsor Name:Avexxin AS
    Full Title: A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Dose-escalation, Single Centre Study to Assess the Safety and Efficacy of AVX001 when Administered Topically Once Daily in...
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000685-12 Sponsor Protocol Number: MC2-01-C6 Start Date*: Information not available in EudraCT
    Sponsor Name:MC2 Therapeutics Ltd
    Full Title: A Multicentre, Open-label, Single-group Maximal Use Trial, Evaluating the Safety and Pharmacokinetic Profile of the Active Ingredients and their Metabolites after application of MC2-01 Cream in Ado...
    Medical condition: Extensive Psoriasis Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-004620-60 Sponsor Protocol Number: CAIN457A2324 Start Date*: 2018-06-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 ...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002640-25 Sponsor Protocol Number: RR12/10234 Start Date*: 2013-02-07
    Sponsor Name:University of Leeds/Leeds Teaching Hospitals NHS Trust
    Full Title: A prospective, single-centre, feasibility study evaluating the prevalence of diagnostic clinical imaging features of subclinical enthesitis in patients with moderate to severe plaque psoriasis and ...
    Medical condition: Psoriatic disease (psoriasis and psoriatic arthritis).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10066579 Progression of psoriatic arthritis LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    14.1 100000004859 10037160 Psoriatic arthritis LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037157 Psoriasis of scalp LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10063407 Psoriasis genital LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10028703 Nail psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000985-39 Sponsor Protocol Number: CAIN457A2304E1 Start Date*: 2012-09-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, double-blind and open label, 4 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) SK (Completed) DE (Completed) AT (Completed) IT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000533-39 Sponsor Protocol Number: CAIN457A2302E1 Start Date*: 2012-06-04
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 2 years in subj...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed) LV (Completed) SE (Completed) LT (Completed) ES (Completed) BE (Completed) EE (Completed) GB (Completed) DE (Completed) FI (Completed) HU (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013037-19 Sponsor Protocol Number: VB-201-006-A Start Date*: 2010-02-08
    Sponsor Name:Vascular Biogenics Ltd.
    Full Title: A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002609-22 Sponsor Protocol Number: CAIN457A2309 Start Date*: 2012-10-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in autoinjectors to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tol...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000524-25 Sponsor Protocol Number: CAIN457A2318 Start Date*: 2017-02-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab, to demonstrate efficacy after twelve weeks of treatment and to assess safety, tolerability and long...
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018190 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 19:30:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA